EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Perspectives on Antimicrobial Agents: Pivmecillinam

Brandon K Hawkins iD, Helen Ding iD, Melphine M Harriott, James L Wang

Antimicrobial Agents and Chemotherapy · 06.08.2025 · 69 (8)

DOI: 10.1128/aac.01824-24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.08.2025. Verfasst von Brandon K Hawkins und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, Tennessee, U…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Urinary Tract Infections, Amdinocillin Pivoxil. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pivmecillinam is a prodrug of mecillinam, a semi-synthetic penicillin, that has recently been U.S. Food and Drug Administration approved for the treatment of uncomplicated urinary tract infections (UTIs) in the United States. Mecillinam demonstrates activity against a variety of common uropathogens, including Enterobacterales such as Escherichia coli and Klebsiella pneumoniae . Despite being available internationally for more than four decades, mecillinam retains high susceptibility rates against a variety of Enterobacterales, including some that produce extended-spectrum-β-lactamases (ESBL) and carbapenemases. Given extensive clinical experience and history with this agent outside the United States, this review highlights the available literature on pivmecillinam regarding susceptibility testing and implementation, empiric antibacterial activity with a focus on ESBL-producing isolates, optimal treatment dose, and duration, as well as adverse effects and tolerability. In the United States, the current lack of approved susceptibility tests will limit pivmecillinam use to empiric therapy. There is significant heterogeneity among clinical studies, limiting the ability to identify an optimal treatment regimen for most pathogens with certainty. Comparative data regarding pivmecillinam against other agents used for UTI treatment are similarly limited but do not suggest it is significantly different in terms of clinical outcomes when considering specific treatment regimens. Clinical data regarding pivmecillinam’s use in UTI due to ESBL-producing Enterobacterales are less robust but appear supportive if used at higher doses and for longer durations. Pivmecillinam is generally well tolerated, with gastrointestinal-related complaints being the most common. In the future, the availability of susceptibility testing and clinical data for pivmecillinam against OXA-48-like-producing Enterobacterales could expand its therapeutic utility for UTI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsUrinary Tract InfectionsAmdinocillin PivoxilHumansMicrobial Sensitivity TestsKlebsiella pneumoniaeEscherichia colibeta-LactamasesEnterobacteriaceae

Stichwörter der Autor:innen

Enterobacteralesamdinocillinclinical dataextended-spectrum beta-lactamase producerspivmecillinamreviewurinary tract infections

Substanzen

Anti-Bacterial AgentsAmdinocillin Pivoxilbeta-Lactamases

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, Tennessee, USA.
  • Department of Pharmacy, University of Tennessee Medical Center, Knoxville, Tennessee, USA.
  • Healthcare-Associated Infections and Antimicrobial Resistance Program of the Communicable and Environmental Diseases and Emergency Preparedness Division, Tennessee Department of Health, Nashville, Tennessee, USA.
  • Division of Infectious Diseases, University of Tennessee Medical Center, Knoxville, Tennessee, USA.
  • Department of Internal Medicine, Graduate School of Medicine, University of Tennessee Health Science Center, Knoxville, Tennessee, USA.

ORCID-Profile: Brandon K Hawkins, Helen Ding

Zitieren

APA

Hawkins, B. K., Ding, H., Harriott, M. M., & Wang, J. L. (2025). New Perspectives on Antimicrobial Agents: Pivmecillinam. Antimicrobial Agents and Chemotherapy, 69(8). https://doi.org/10.1128/aac.01824-24

Vancouver

Hawkins BK, Ding H, Harriott MM, Wang JL. New Perspectives on Antimicrobial Agents: Pivmecillinam. Antimicrobial Agents and Chemotherapy. 2025;69(8). doi:10.1128/aac.01824-24

BibTeX
@article{Hawkins2025,
  author = {Hawkins, Brandon K and Ding, Helen and Harriott, Melphine M and Wang, James L},
  title = {New Perspectives on Antimicrobial Agents: Pivmecillinam},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {8},
  doi = {10.1128/aac.01824-24}
}
Kostenlos starten →